Related Experiment Video
Updated: Jun 3, 2025
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
8.8K
The IL-23R and Its Genetic Variants: A Hitherto Unforeseen Bridge Between the Immune System and Cancer Development
Salvatore Audia1, Carolina Brescia1, Vincenzo Dattilo2
1Immuno-Genetics Lab, Department of Health Science, Medical School, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
Cancers
|January 11, 2025
Summary
The interleukin-23 receptor (IL-23R) is vital for immune responses and linked to autoimmune diseases and cancer. Targeting the IL-23/IL-23R pathway offers promising therapeutic strategies for various conditions.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- The interleukin-23 receptor (IL-23R) is expressed on immune cells, regulating adaptive immunity and inflammatory responses.
- IL-23R signaling is crucial for T helper 17 (Th17) cell function, which are implicated in autoimmune diseases, inflammation, and cancer.
Purpose of the Study:
- To review the role of IL-23R in immune genetics.
- To explore the potential of IL-23R in modulating neoplastic disease progression and therapeutic response.
Main Methods:
- Literature review of studies on IL-23R function.
- Analysis of IL-23R's association with immune-related genetic factors.
- Examination of IL-23R's role in autoimmune diseases, cancer, and infection.
Main Results:
- IL-23R is associated with susceptibility and resistance to diseases like psoriasis, ankylosing spondylitis, and inflammatory bowel disease (IBD).
- The IL-23/IL-23R pathway is a potential biomarker for tumor progression and treatment response.
- The IL-23/IL-23R pathway is a promising therapeutic target, with drugs like monoclonal antibodies in development to reduce inflammation.
Conclusions:
- IL-23R plays a significant role in immune genetics and disease pathogenesis.
- Targeting the IL-23/IL-23R pathway represents a novel therapeutic avenue for inflammatory conditions and cancers.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
375
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.1K
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:24T Cell Types and Functions
946
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
946
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K